Novartis is returning to Huntington's disease with a $1 billion upfront bet, plus another $1.9 billion in biobucks, for ...
Merus reported updated Phase 2 trial results for petosemtamab in head and neck cancer, showing 40.4% overall response rate ...
Apogee Therapeutics plans to challenge Sanofi and Regeneron's Dupixent with its lead drug APG777, an IL-13 targeting ...
The FDA rejected Applied Therapeutics’ experimental treatment, govorestat, for a rare disease called classic galactosemia, ...
Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva
Advanz Pharma's liver treatment Ocaliva lost EU marketing authorization following a court decision. The drug, used for ...
FDA accepts Satsuma Pharmaceuticals' NDA resubmission for STS101 migraine drug. Hovione expands facilities in Ireland and New ...
Novartis is laying off 139 employees in East Hanover, NJ, as the company shifts its commercial resources away from two “well-established” medicines.
Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model for distributing 340B drug … ...
Outlook Therapeutics' ONS-5010 (bevacizumab) failed to meet its primary endpoint in a Phase 3 trial against Roche's Lucentis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback